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Abstract
Present investigations suggest that approximately 30% of colorectal cancer (CRC) cases arise on
the basis of inherited factors. We hypothesize that the majority of inherited factors are moderately
penetrant genes, common in the population. We use an affected sibling pair approach to identify
genetic regions that are coinherited by siblings with CRC. Individuals from families with at least
two siblings diagnosed with colorectal adenocarcinoma or high grade dysplasia were enrolled.
Known familial CRC syndromes were excluded. A genome-wide scan on 151 DNA samples from
70 kindreds was completed using deCODE's 1100 short tandem repeat marker set at an average 4
cM density. Fine mapping on a total of 184 DNAs from 83 kindreds was done in regions
suggesting linkage. Linkage analysis was accomplished with MERLIN analysis package. Linkage
analysis revealed three genetic regions with NPL LOD scores ≥ 2.0: Ch. 3q29, LOD 2.61
(p=0.0003); Ch. 4q31.3, LOD 2.13 (p=0.0009); and Ch. 7q31.31, LOD 3.08 (p=0.00008).
Affected siblings with increased sharing at the 7q31 locus have an 3.8 year (±3.5) earlier age of
CRC onset although this is not statistically significant (p=0.11). No significant linkage was found
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near genes causing known syndromes or, regions previously reported (8q24, 9q22, and 11q23).
The chromosome 3q21-q24 region reported to be linked in CRC relative pairs, is supported by our
study, albeit a minor peak (LOD 0.9, p=0.02). No known familial cancer genes reside in the 7q31
locus, thus the identified region may contain a novel susceptibility gene responsible for common
familial CRC.
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Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death and is one of the
most familial malignancies 1. Approximately 10% of the U.S. population has at least one
first-degree relative with colorectal cancer 2. Kindred and twin studies estimate that as much
as 35% of the risk for colorectal adenocarcinoma is attributable to heredity 3,4. The known
inherited colon cancer syndromes, however, account for less than 5% of CRC, leaving the
genetic etiology unknown for the majority of familial CRC cases.
Association studies have reported a few low-penetrance genetic variants associated with
colon cancer risk that could account for a yet to be defined proportion of the familial CRC
cases 5,6. Affected-relative-pair studies have also reported genetic regions that are
coinherited more often in first-degree relatives with CRC than those without. These include
9q22.33, 3q21-24, and 11q23 7-10. A continued combination of association and linkage
approaches will be important to defining new genes that predispose to common familial
CRC and will in turn allow the synthesis of more risk directed CRC prevention and
mortality reduction efforts.
Here we report the results of a genome-wide linkage analysis using 83 kindreds where at
least two siblings were diagnosed with colorectal cancer (invasive or high grade dysplasia).
A set of 1100 highly-polymorphic short tandem repeat markers were used for genotyping
(deCODE 4cM set) of the affected sibships. The results provide strong evidence for linkage
of CRC to a locus at 7q31 and support linkage to the previously reported 3q21-q24 locus 9.
Materials and Methods
Ascertainment and collection of colon cancer sibling pairs
Subjects were enrolled in the Inheritance of Colon Cancer: A Sibling Pair Study following
review and approval by the Institutional Review Boards of the eleven participating centers.
Informed consent was obtained from all research participants. Kindreds were ascertained
from Cancer Genetics Network members, population-based county-wide or state-wide
cancer registries, clinical referral and direct-to-patient marketing. Each family had at least
two individuals diagnosed with colorectal adenocarcinoma, or a polyp with high-grade
dysplasia (also reported as carcinoma in situ, which is synonymous with the previous term)
over the age of 20. Diagnosis was confirmed by pathology reports in most cases or cancer
registry data. A total of 274 individuals were enrolled in the study, however 88 individuals
were excluded from linkage analysis because a sibling was not enrolled (deceased or not
interested) or they a known colon cancer syndrome. In the end, 186 DNAs constituted a
complete sibship and were used for linkage analysis.
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Ruling out of known syndromes
Families with known colon cancer syndromes including familial adenomatous polyposis,
Juvenile Polyposis, Puetz-Jeghers, and Cowdens syndrome were excluded by medical record
review. A small possibility exists that families with attenuated or MYH polyposis could
enter the study, but given the rarity of these conditions and the chance that at least one
sibling would have a clinically recognizable condition (≥ 10 adenomas) resulting in study
exclusion, their inclusion would be very minor effect. When tumor blocks were available on
one or more colon cancer cases, microsatellite instability (MSI) analysis was performed as
previously described 11,12 to rule out Hereditary nonpolyposis colorectal cancer (HNPCC
of Lynch Syndrome). Genomic DNA from cases that demonstrated MSI-high was
sequenced for mutations in MLH1 and MSH2. Five mutation positive families were
excluded from the analysis. Individuals who were confirmed to have a known syndrome
were referred to a genetic counselor and clinical genetic testing was offered.
Genotyping and linkage analysis
A genome scan was performed on 138 affected and 13 unaffected siblings composing 70
kindreds (64 complete affected sibships of pairs (60) or trios (4)) using deCODE's 1100
short tandem repeat (STR) marker set at an average 4 cM density 13. Fine mapping included
40 STR markers run on 184 individuals from 83 kindreds (163 affected and 21 unaffected).
This contained 75 complete affected sibships of pairs (71) or trios (4). Unaffected siblings
were available on 16 kindreds, however there was insufficient data for discordant analysis
(32 discordant relationships; 5 concordant unaffected relationships).
Genome-wide nonparametric linkage analysis was performed with Merlin 14 using the Kong
and Cox linear model 15, and Whittemore and Halpern's Sall sharing statistic 16. Parametric
dominant model was run with a disease allele frequency of 0.001 and an absolute disease
risk of 0.025 for non-carriers and 0.5 for carriers. Parametric recessive model was run with
an allele frequency of 0.05 and disease risk of 0.025 for noncarriers and heterozygotes, and
0.05 for homozygous carriers. Individuals were coded as affected if they had a confirmed
diagnosis of invasive CRC or a colonic adenoma with high grade dysplasia or carcinoma in
situ. Linkage analysis was run using two sources of allele frequencies for each marker; both
are represented in Figure 1. The first was 157,810 genotypes generated from the complete
data set (sibpair allele frequencies). The second was a set of 8000 genotypes from 13 CEPH
parents who were part of HapMap. The CEPH DNAs were collected in 1980 from U.S.
residents with northern and western European ancestry by the Centre d'Etude du
Polymorphisme Humain (CEPH) and have been used as a reference panel for establishing
genetic maps of the human genome including the HapMap, a catalog of common genetic
variants that occur in human beings.
To assess the association of allele sharing with variation in quantitative pathology traits we
used the Variance Components module of Merlin which regresses the pairwise covariation
of trait values against the identical by descent (IBD) sharing for each marker. Age at
diagnosis, tumor grade (grade 1 is well differentiated, grade 2 is moderately differentiated,
grade 3 is poorly differentiated), tumor location (right-sided cancers are defined as proximal
to the splenic flexure), tumor size at largest dimension, lymph node involvement, and cancer
stage (0-4) were modeled as continuous traits. MSI status was available on too few cases to
use this as a covariate.
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Characteristics of affected individuals
The mean age of colorectal cancer diagnosis was 58.3 (std. dev. ± 12.5) with a range of 28
to 91 years and a median of 60 years. Carcinoma in situ or high-grade dysplasia was the
diagnosis in 14% of the cases, lymph node involvement was found in 30% of the cancers,
and 12% had metastasized to other tissues. Cancer staging was available on 76% of the
cases. Of these, 33% were Stage 1, 30% were Stage 2, 27% were Stage 3 and 10% were
Stage 4. The racial make-up of the participants was 87% white, 4% black, 1% Native
American, and 8% other. The ratio of affected males to affected females was nearly equal
(82:81). MSI analysis was performed on at least one colorectal tumor from 46 of the 83
families. Of the 46 families, 39 were microsatellite stable or low, four had microsatellite
unstable cancers, and three had both stable and unstable cancers. Germline mutations in
MLH1 and MSH2 were not identified in five of the seven MSI unstable cases. Two did not
undergo sequencing.
Genotyping and linkage analysis
A genome-wide scan on 151 samples from 70 kindreds was completed using deCODE's
1100 STR marker set at an average 4 cM density. All DNA samples successfully amplified,
however two samples had low yield. Excluding these two samples, 91.9% of the genotypes
were successfully obtained. Fine mapping on a total of 184 DNAs (163 affected and 21
unaffected) from 83 kindreds was done using 40 additional deCODE markers at peaks
identified in the genome scan on chromosomal regions 4q24-4q26, 4q31-4q32, 7q11-7q22,
and 7q31-7q33. In this 40 marker fine mapping run, 96.5% of the genotypes were
successful.
Multipoint nonparametric linkage analysis identified three regions with NPL LOD scores
greater than 2.0 on chromosomes 3q29 (tel), 4q31.3, and 7q31 (Figure 1 and Table 1). Of
these, the 7q31.31 region spanned 13.6 cM (22.63 Mbp) with a maximum NPL LOD of 3.08
and a p=0.00008 (CEPH allele frequencies) or 2.01 and p=0.001 (study allele frequencies) at
D7S643. The peak contains 96 RefSeq genes. No known familial cancer genes reside within
this region, thus the identified region may contain a novel susceptibility gene responsible for
common familial colorectal cancer. Two genes in this region are involved in cancer
development 17: MET, a proto-oncogene and hepatocyte growth factor receptor involved in
hepatocellular carcinoma and SMO, a G protein-coupled receptor involved in basal cell
carcinoma. Candidate cancer genes in this region were also identified from a list of genes
hypothetically involved in cancer based on similarity in Gene Ontology (GO term) and
sequence properties to a set of 291 genes known to be involved cancer development 17,18.
Seven of these genes were predicted to have greater than 80% probability of being involved
in cancer development: PAX4, DOCK5, TFEC, FOXP2, NRF1, and IRF5. Other interesting
candidate genes in this region are GPR37, G protein-coupled receptor 37 which is an
endothelin receptor type B-like, and two WNT ligands involved in the APC/beta-catenin
signaling pathway, WNT2 and WNT16.
The results of parametric analysis under dominant and recessive models using study allele
frequencies are presented in the supplementary data (Figure S1). The parametric models do
not fit the data very well, suggesting that the parameter values supplied are not very realistic.
The recessive model identifies a novel peak with a LOD of 2.7 (p=0.0004) at D2S2358. The
gene for epidermal growth factor receptor 4 (ERBB4) resides close to this peak and has been
associated with a small percentage of colorectal cancers 19-21.
There were no major peaks near genes know to cause colon cancer syndromes (MLH1,
MSH2, MSH6, PMS2, APC, MYH, SMAD4, BMPR1A, PTEN, STK11). However a minor
Neklason et al. Page 4













peak is observed near MLH1 (62.7cM) at D3S1612 (60.05 cM) with a LOD of 1.25
(unadjusted p=0.008). This is only present when CEPH allele frequency is used, which may
be an artifact or may represent a D3S1612 allele segregating with a common, mildly
penetrant MLH1 variant predisposing siblings to developing colorectal cancer. Linkage
analysis was also run excluding the 7 families with at least one microsatellite unstable
cancer (supplementary data, Figures S2 and S3). The results of this analysis appear very
similar to the full dataset and the peak near MLH1 is not eliminated (supplementary data,
Figure S4).
The 8q24 region recently associated with colorectal cancer risk was not supported by this
study 6,22,23. The chromosome 9q22.33 region previously reported to be linked in affected
relative pairs with advanced adenomas and colon cancers, was also not confirmed by this
study 7,9. Each of the markers in the 9q22.33 region gave negative LOD scores. However,
the chromosome 3q21-q24 region reported to be linked in colorectal cancer relative pairs is
supported by our study, albeit a minor peak at D3S1292 (LOD 0.9 p=0.02) 8.
Characteristics of siblings that share the 7q31.31 locus
Pathology features of the colorectal cancers from the affected sibling pairs were analyzed to
determine if coinheritance at the 7q31 locus was associated with any particular trait.
Pairwise covariation for age of CRC diagnosis, histologic grade (1-3), location of cancer
(right vs. left sidedness), size of tumor, and lymph node involvement, and stage of CRC was
regressed against the IBD sharing at this locus. Only age of diagnosis and grade of cancer
contributed to the heritability, however, neither was significant (Table 2). Poorly
differentiated tumors were more likely to be seen with increased sharing at 7q31. Of note is
the trend toward younger age of onset of CRC with increased sharing at 7q31. Linear
regression of age of diagnosis versus identity by descent (IBD) showed that the mean age of
diagnosis decreases by 3.8 years as IBD goes from 0 to 1 alleles (std. err. ±3.5).
Discussion
Using the affected sibling-pair approach to identify genetic regions involved in common
familial colorectal, a major locus has been identified on chromosome 7q31. This region
clearly stands out from the rest of the genome demonstrating linkage at multiple genetic
markers over a 13.6 cM region when either study allele frequencies or CEPH allele
frequencies are used in the analysis. A region on chromosome 7 with linkage (NPL LOD
1.85, p=0.032) is also reported by Kemp et al. when analysis was restricted to 38 families
with colorectal cancer as the diagnosis 8. The reported peak spans approximately 80 to 110
Mbp, whereas our peak spans 107 to 129 Mbp on chromosome 7.
Interestingly, LOH of one or more markers in the 7q31.1-31.2 around marker D7S522
region has been reported in a series of 11 of 18 colon carcinoma cases, with the maximum
LOH at D7S522 (115.9 Mbp), within the region identified in this study. The authors suggest
that a tumor suppressor gene relevant to the development of epithelial cancers is present in
this region 24. Certainly, the MET gene is in this region of LOH at 116.1 Mbp.
Additionally, the ERBB4 gene is near a peak identified through the recessive parametric
model on 2q33.3. A functional polymorphism at -782G>T in this gene was recently reported
as a risk factor in colorectal cancer (OR 2.21, 95% CI 1,22-3.99) and will be important to
examine in this sibling pair population 19.
The study was originally designed to be much larger based on modeling and power
estimates to detect linkage as described by Kerber et al., 2008 25(manuscript in press).
Considering the minimum observed p-value of 0.0001 as a critical threshold, and taking the
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relatively conservative value of 0.2 as an estimated attributable risk for inherited
susceptibility to colon cancer, we see reasonable (≥ 10%) power only if this locus accounts
for the majority of the heritable effect, either because of high penetrance or high prevalence.
It is not clear that the majority of heritable CRCs can be explained by variation at this locus,
so we might wish to consider alternative explanations. Two details of the modeling may
have resulted in over-conservative power estimates when compared to the study as we have
actually carried it out: 1) the markers employed are far more heterogeneous than the 4-allele
markers simulated; and 2) the multipoint methods employed in the present study using
intervals of 1 cM may have considerably more power than the simulated tests. These two
factors probably interact to increase power, so estimates may be quite conservative.
Nevertheless, the p-values we have observed are surprisingly small considering the study
design and sample size.
Although this is one of the largest colorectal cancer sibling-pair studies reported thus far, a
major limitation is nonetheless its size, 75 families with DNA from two or more affected
individuals. A strength as well as a challenge of our study was to restrict enrollment to
individuals with invasive colorectal cancer or an adenoma with high grade dysplasia or
carcinoma in-situ. This was a challenge due to the high mortality of colorectal cancer; it was
difficult to enroll two siblings surviving colorectal cancer and willing to participate in
research. Other groups have done similar studies, but included fewer families and less
penetrant phenotypes, such as the presence of advanced adenomas (≥1cm) 7 or any colonic
polyp including benign hyperplastic polyps 8. As Kemp et al. report, distinct genetic loci are
identified when the study set is restricted to colorectal cancer.
Use of the CEPH allele frequencies for linkage analysis consistently results in higher LOD
scores (vs. the study allele frequencies). This is most likely due to minor alleles being over
represented in the CEPH data set. Since the CEPH allele set is limited to 13 individuals and
5% the size of the study allele set, this is not surprising. The one peak on chromosome 3,
using only CEPH allele frequencies, is interesting in that it is close to MLH1 and might
represent a marker commonly found in the study population and linked to a pathogenic
MLH1 variant.
Further confirmatory studies as well as expansion of the study population size are needed to
confirm this 7q31 locus and identify other genetic loci contributing to hereditary colorectal
cancer risk in the population. Investigation of genes within this region will be equally
important, especially regulatory or coding SNPs that may be enriched in the colorectal
cancer population. Finally, evaluation of LOH in tumor blocks in regions showing linkage,
especially the 7q31 region which has demonstrated LOH in sporadic colorectal cancers,
would provide further evidence for region containing a tumor suppressor gene responsible
for familial colorectal cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Linkage analysis of genome scan
Multipoint nonparametric linkage analyses using sibpair study allele frequencies (red line)
or CEPH Caucasian control allele frequencies (green line) are shown. The cumulative
chromosome length is based on the DeCode genetic map. Each chromosome boundary is
indicated by a blue vertical line. Genes known to cause colon cancer syndromes are noted on
the map.
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